Fenoldopam in newborn patients undergoing cardiopulmonary bypass: Controlled clinical trial

Interactive Cardiovascular and Thoracic Surgery

Volumn 7, Issue 6, 2008, Pages 1049-1053

  Ricci, Zaccaria ^a   Stazi, Giulia V ^a   Di Chiara, Luca ^a   Morelli, Stefano ^a   Vitale, Vincenzo ^a   Giorni, Chiara ^a   Ronco, Claudio ^b   Picardo, Sergio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Acute kidney injury; Cardiopulmonary bypass; Congenital heart disease; Fenoldopam

Indexed keywords

ADRENALIN; CREATININE; DOPAMINE; FENOLDOPAM; FUROSEMIDE; HEMOGLOBIN; MILRINONE; POTASSIUM; SODIUM;

AORTA ARCH INTERRUPTION; ARTICLE; BLALOCK TAUSSIG SHUNT; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; EXTUBATION; FALLOT TETRALOGY; FLUID BALANCE; GREAT VESSELS TRANSPOSITION; HEART SURGERY; HEART VENTRICLE SEPTUM DEFECT; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOPLASTIC LEFT HEART SYNDROME; HYPOTENSION; INOTROPISM; KIDNEY FUNCTION; KIDNEY INJURY; LOW DRUG DOSE; NEWBORN; NEWBORN INTENSIVE CARE; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; URINE VOLUME;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CREATININE; DOPAMINE AGONISTS; FENOLDOPAM; HEMODYNAMICS; HUMANS; INFANT, NEWBORN; INFUSIONS, PARENTERAL; INTENSIVE CARE; KIDNEY DISEASES; PATIENT DISCHARGE; POTASSIUM; PROSPECTIVE STUDIES; RESPIRATION, ARTIFICIAL; SODIUM; STERNUM; TIME FACTORS; TREATMENT OUTCOME; URINATION; URODYNAMICS; WATER-ELECTROLYTE BALANCE;

EID: 57349151494     PISSN: 15699293     EISSN: None     Source Type: Journal    
DOI: 10.1510/icvts.2008.185025     Document Type: Article

References (16)

1. Seghaye MC, Engelhardt W, Garbitz RG, Faymonville ME, Hornchen H, Messmer BJ, von Bernuth G. Multiple systems organ failure after open heart surgery in infants and children. Thorac Cardiovasc Surg 1993;41:49-53.
2. Aravindan N, Natarajan M, Shaw AD. Fenoldopam inhibits nuclear translocation of nuclear factor kappa B in a rat model of surgical ischemic acute renal failure. J Cardiothorac Vasc Anesth 2006;20:179-186.
3. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001;345:1548-1557.
4. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabro MG, Ranucci M, Zangrillo A. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007;49:56-68.
5. Costello JM, Thiagarajan RR, Dionne RE, Allan CK, Booth KL, Burmester M, Wessel DL, Laussen PC. Initial experience with fenoldopam after cardiac surgery in neonates with an insufficient response to conventional diuretics. Pediatr Crit Care Med 2006;7:28-33.
6. Larsen SH, Pedersen J, Jacobsen J, Johnsen SP, Hansen OK, Hjortdal V. The RACHS-1 risk categories reflect mortality and length of stay in a Danish population of children operated for congenital heart disease. Eur J Cardiothorac Surg 2005;28:877-881.
7. Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 2007;71:1028-1035.
8. Shore S, Nelson D, Pearl J, Manning P, Wong H, Shanley T, Keyser T, Schwartz S. Usefulness of corticosteroid therapy in decreasing epinephrine requirements in critically ill infants with congenital heart disease. Am J Cardiol 2001;88:591-594.
9. Lokhandwala MF, Barrett RJ. Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications. J Auton Pharmacol 1982;2:189-215.
10. Weber RR, McCoy CE, Ziemniak JA, Frederickson ED, Goldberg LI, Murphy MB. Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. Br J Clin Pharmacol 1988;25:17-21.
11. Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 2005;46:26-34.
12. Bove T, Landoni G, Calabro MG, Aletti G, Marino G, Cerchierini E, Crescenzi G, Zangrillo A. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005;111:3230-3235.
13. Strauser LM, Pruitt RD, Tobias JD. Initial experience with fenoldopam in children. Am J Ther 1999;6:283-288.
14. Moffett BS, Orellana R. Use of fenoldopam to increase urine output in a patient with renal insufficiency secondary to septic shock: a case report. Pediatr Crit Care Med 2006;7:600-602.
15. Cheung PY, Barrington KJ. Renal dopamine receptors: mechanisms of action and developmental aspects. Cardiovasc Res 1996;31:2-6.
16. Moffett BS, Mott AR, Nelson DP, Goldstein SL, Jefferies JL. Renal effects of fenoldopam in critically ill pediatric patients: a retrospective review. Pediatr Crit Care Med 2008; PMID: 18496409.